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IHCAbstract Background: Gastric cancer is one of the most common cancers and the second most
common cause of cancer-related death worldwide. Identiﬁcation of speciﬁc prognostic indicators
might allow a better prognostic stratiﬁcation and more effective therapy.
Aim: To assess the expression and relationship between COX-2 and VEGF protein in gastric ade-
nocarcinoma and whether these markers are useful in predicting clinicopathological prognostic
parameters.
Materials and methods: The study included 83 formalin-ﬁxed parafﬁn embedded tissue samples of
excised gastric adenocarcinoma and 20 non tumorous tissue controls. The slides were subjected to
COX-2 and VEGF immunohistochemical staining using a streptavidin–biotinperoxidase according
to the manufacturer’s protocol. The results were assessed independently by two pathologists. The
relationships among COX-2 and VEGF expression and clinicopathological parameters were statis-
tically analyzed.
Results: COX-2 and VEGF expressions were obviously higher in carcinoma tissues compared to
normal mucosae (p< 0.001). The expression rate of COX-2 was 54.2% and of VEGF was
68.7%. COX-2 positive tumors were signiﬁcantly correlated with Lauren classiﬁcation, tumor depth
and Helicobacter pylori infection (p< 0.001, p= 0.008, p= 0.035). VEGF was signiﬁcantly asso-
ciated with lymph node metastasis and tumor depth (p< 0.001). There was a positive association
between VEGF and COX-2 expression in gastric adenocarcinoma (Kappa value = 0.55).
Conclusion: In gastric adenocarcinoma, COX-2 expression might serve as a powerful indicator for
intestinal type carcinoma, locally advanced disease and H. pylori infection, while VEGF was related
to loco-regional progression. COX-2 might be involved in the development of angiogenesis in gas-
tric carcinoma through VEGF upregulation.
 2016 National Cancer Institute, Cairo University. Production and hosting by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Gastric cancer (GC) is one of the most common cancers world-
wide with a relative frequency of 7.8% of all cancers [1,2].
More than 90% of gastric cancers are adenocarcinomas. In
the latter half of the twentieth century, GC was the second
most common cause of cancer-related deaths after lung carci-
noma accounting to 11.3% of all cancer deaths [3]. In Egypt,
GC represented 1.6% of all cancers and 2.2% of all cancer
mortality [4]. According to the registry of the Egyptian
National Cancer Institute, GC formed 2.12% of total malig-
nancy and 10.3% of gastrointestinal cancers [5].
Despite advances in diagnosis and treatment, the prognosis
of patients with GC has remained unsatisfactory. Nearly one-
third of the patients (29.9%) experienced recurrence after
gastric surgery. It is the main cause of cancer related death
[6]. One major difﬁculty in the therapy of GC is the presence
of only few prognostic indicators that can predict its clinical
behavior. Therefore, identiﬁcation of other speciﬁc prognostic
markers might allow a better prognostic stratiﬁcation and thus
more effective therapy [3].
Cyclooxygenase (COX) is a key enzyme in prostaglandin
synthesis from arachidonic acid. There are two enzyme forms,
COX-1 isoform, a component of the normal cells that has been
connected to physiological functions, and the COX-2 isoen-
zyme that is frequently undetectable in most normal tissues
[6]. Overexpression of COX-2 protein has been detected in
some tumors including GC. It was reported that its overex-
pression is associated with poor prognosis and reduced sur-
vival [7]. The mechanism by which COX-2 induces
carcinogenesis is not known until now. COX-2 enzyme may
stimulate cell proliferation, inhibit apoptosis, increase inva-
siveness and induce angiogenesis by elaborating some angio-
genic factors such as vascular endothelial growth factor
(VEGF) [8].
Angiogenesis plays a critical role in tumor progression and
metastasis. In the vast majority of malignancies, including gas-
trointestinal neoplasms, angiogenesis has been associated with
poor prognosis and relapse of the tumor. The best known and
the most efﬁcient angiogenic growth factor is VEGF [9].
VEGF is known to accelerate endothelial cellular prolifera-
tion, vascular permeability, and endothelial cell migration,
and inhibit apoptosis, whereas inhibition of VEGF results in
suppression of tumor growth [10].
The aim of the current study is to assess: COX-2 and VEGF
immunohistochemical (IHC) expression in GC cases, whether
these markers are useful in predicting clinicopathological prog-
nostic parameters and whether there is an association between
the expression of COX-2 and VEGF.
Materials and methods
The present retrospective study included 83 patients with
histopathologically proven gastric adenocarcinoma who
underwent curative surgical resections that were retrieved from
the ﬁles of Pathology Department, National Cancer Institute,
Cairo University between June 2008 and December 2014. The
control group included 20 cases with non neoplastic gastric tis-
sues that underwent endoscopic biopsy during the same per-
iod. All specimens were taken from the archives of the
Pathology Department.Clinicpathological data including age, sex, location, histo-
logical type, grade, depth of invasion, nodal status and
Helicobacter pylori (H. pylori) infection in the non neoplastic
adjacent mucosa were determined from the pathology reports.
The eligibility criteria included: histopathologically proven
gastric adenocarcinoma classiﬁed according to the World
Health Organization classiﬁcation [11], no neoadjuvant
chemotherapy and/or radiotherapy and availability of com-
plete clinicalpathological data.
Immunohistochemical method
The archival histopathological slides of all studied cases were
reviewed to conﬁrm the diagnosis, to detect H. pylori in the
adjacent mucosa in some cases and to choose the appropriate
parafﬁn embedded tissue blocks for sectioning and IHC stain-
ing. For each case; two serial sections, of 4 lm thickness were
cut by the microtome then mounted onto positively charged
slides.
The slides were subjected to IHC staining using a streptavi
din–biotin-peroxidase according to the manufacturer’s proto-
col using BenchMark XT automated slide stainer (a product
of Ventana Medical Systems). All sections were deparafﬁnized
by xylene, rehydrated by a graded series of ethanol, and trea-
ted with 0.3% H2O2 for 5 min at room temperature to block
endogenous peroxidase activity. Heat-based antigen retrieval
was performed to obtain optimal results. Sections were treated
with 5% bovine serum albumin to block non-speciﬁc staining.
The slides were incubated with the primary antibody, anti-
COX-2 antibody (monoclonal rabbit anti-human, clone SP2,
in a dilution of 1:100, Thermo Scientiﬁc, USA) and anti-
human VEGF antibody (monoclonal mouse, clone VG1,
M7273, DakoCytomation, Denmark, at a 1:50 dilution).
Diaminobenzidine was used as a chromogen and hematoxylin
as a counterstain.
Appropriate positive and negative controls were included in
each IHC run. Negative controls were prepared by replacing
the primary antibody with Phosphate Buffered Saline (PBS).
Positive staining controls for COX-2 included sections of colo-
nic carcinoma. Positive staining controls for VEGF included
sections of hemangioma tissue
Evaluation of immunohistochemical staining
The expression of COX-2 and VEGF were assessed indepen-
dently by two pathologists who were blinded to the clinico-
pathological parameters of the patients. COX-2 and VEGF
immunoreactivity was detected in the cytoplasm of the cells.
The IHC score was calculated by adding the percentage of pos-
itively stained cells to the staining intensity. The percentage of
positive cells ranged between 0 and 3, i.e. 0, if less than 10%
of tumor cells were stained; 1, if 10–25% of tumor cells were
stained; 2, if 25–50% were positive; and 3, if >50% were posi-
tive. The staining intensity was scored as: 0, negative immunore-
action; 1, weak intensity; 2, moderate intensity; and 3, strong
intensity. The sum of the two parameters varied between 0
and 6. In our study, we considered: a negative immunoreaction
(), for scores between 0 and 2; a weakly positive immunoreac-
tion (+), for scores 3 and 4; a strongly positive immunoreaction
(++), for scores 5 and 6. Cases with scores equal to or higher
than 3, were considered as positive [8,12].
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Statistical analyses were performed with SPSS 11.5 software
(SPSS Inc, Chicago, USA). The correlation between COX-2
and VEGF protein expressions and clinicopathological charac-
teristics were evaluated by Fisher’s exact and chi-square test
for categorical variables. P value less than 0.05 was considered
statistically signiﬁcant. Kappa statistics was used to assess the
level of agreement between COX-2 and VEGF expression;
Kappa values ranging from 0.61 to 0.8 were assumed to indi-
cate a very good agreement.
Results
The studied patients consisted of 60 males (72.3%) and 23
females (27.7%) with male: female ratio of 2.6:1. Ages ranged
between 36 and 88 years old with a mean age of 53 years with
standard deviation of 6.192. The control group included 11
males (55%) and 9 females (45%) ranging between 22 and
63 years with a mean age of 48.1 years.
Analysis of COX-2 immunoreactivity
We investigated the IHC expression of the COX-2 protein in
83 GC tissues and in 20 non cancerous gastric mucosae.
COX-2 expression was signiﬁcantly higher in gastric cancer tis-
sues vs. control mucosae (p< 0.001) (Table 1).
COX-2 expression was noted in 45 (54.2%) of the 83 stud-
ied GC cases (Table 1). The expression rate of COX-2 was
54.2%. The majority of positive cases (32/45) exhibited strong
expression for COX-2 protein, score++, while 13 cases exhib-
ited weak expression, score+ (Table 2, Figs. 1–3).
Thirty four cases (41%) of gastric carcinoma were associ-
ated with intestinal metaplasia in neighboring mucosae. In
16 cases (47.1%), epithelial cells in the adjacent intestinal
metaplastic region showed COX-2 staining (score+). Ten
out 83 gastric carcinoma cases (12%) were associated with dys-
plasia, 4 cases (40%) were associated with COX-2 expression
in these dysplastic epithelial cells (score+).
Clinical and pathological characteristics of the 83 studied
GC patients are listed in Table 3. We assessed the relationship
between COX-2 expression and various clinicopathological
parameters (Table 3). COX-2 positive tumors were noted in
33 (73.3%) GC cases of the intestinal-type and in 12 (31.6%)
of the diffuse type, the expression was signiﬁcantly higher in
the intestinal than in the diffuse carcinomas (p< 0.001). The
COX-2 expression was signiﬁcantly correlated with the depth
of invasion (p= 0.008). COX-2 positive tumors were signiﬁ-
cantly detected among H. pylori infected patients
(p= 0.035). Among the histological subtypes, COX-2Table 1 COX-2 and VEGF protein expression in cancer and contr
Cases No. COX-2 expression
+ve ve
Gastric cancer 83 45 38
Control 20 1 19expression was lower in signet-ring cell carcinoma and undif-
ferentiated carcinoma than other subtypes; however the statis-
tics were not valid as the numbers of some subtypes were very
low.
There were no signiﬁcant relationships between the levels of
COX-2 expression and each of age, sex, location, grade of the
tumor and lymph node status (p> 0.05)
Analysis of VEGF immunoreactivity
VEGF expression was observed in the cytoplasm of cancer
cells. Fifty seven out of eighty three cases (68.7%) were VEGF
positive. VEGF expression was signiﬁcantly higher in gastric
cancer tissues vs. the control mucosae (p< 0.001) (Table 1).
Weak expression, score+, was found in 35 cases while strong
expression, score++, was observed in 22 cases (Table 2). Ten
out of thirty four cases with intestinal metaplasia in the adja-
cent mucosa (29.4%) were positive for VEGF (score+) in
the metaplastic area (score+). Five of ten (50%) dysplasias
of the stomach were positive for VEGF (score+) (Figs. 4
and 5).
The associations between VEGF expression and the clinico-
pathological parameters are shown in Table 4. VEGF positiv-
ity was signiﬁcantly higher in patients with lymph node
metastasis than in those without (p< 0.001). VEGF expres-
sion was signiﬁcantly correlated with the depth of invasion.
The frequency of VEGF positive tumors was signiﬁcantly
higher in stages T3 and T4 than in the T1 and T2 (p< 0.001).
There were no signiﬁcant relationships between VEGF
expression and each of age, sex, location, grade of the tumor,
Lauren classiﬁcation, histological subtypes and H. pylori infec-
tion (p> 0.05)
Relationship between COX-2 and VEGF
In order to evaluate the relation between the IHC expression
of COX-2 and tumor angiogenesis, we have evaluated the asso-
ciation between VEGF and COX-2 expression (Table 5).
VEGF was higher in patients with COX-2 expression than in
those without. Kappa value was 0.55 indicating a moderate
agreement between COX-2 and VEGF expression.ol cases.
P value VEGF expression P value
+ve -ve
<0.001 57 26 <0.001
0 20
Table 3 Relationship between COX-2 expression and the clinicopathological factors of the 83 studied GC cases.
Clinicopathological factors Total COX-2 expression P value
+ve (n= 45) ve (n= 38)
Age
<60 years 44 23 (52.3%) 21 (47.7%) 0.706
P 60 years 39 22 (56.4%) 17 (43.6%)
Sex
Male 60 35 (58.3%) 25 (41.7%) 0.224
Female 23 10 (43.5%) 13 (56.5%)
Location
Antrum 41 22 (53.7%) 19 (46.3%) 0.943
Body 20 11 (55%) 9 (45%)
Fundus 17 9 (52.9%) 8 (47.1%)
Cardia 5 3 (60%) 2 (40%)
Lauren classiﬁcation
Intestinal type 45 33 (73.3%) 12 (26.7%) <0.001
Diﬀuse type 38 12 (31.6%) 26 (68.4%)
Histologic subtypes
Tubular adenocarcinoma 33 25 (75.8%) 8 (24.2%) NA*
Papillary adenocarcinoma 6 4 (66.7%) 2 (33.3%)
Mucinous adenocarcinoma 7 5 (71.4%) 2 (28.6%)
Signet ring adenocarcinoma 31 10 (32.3%) 21 (67.7%)
Undiﬀerentiated carcinoma 6 1 (16.7%) 5 (83.3%)
Grade
1 6 3 (50%) 3 (50%) 0.732
2 50 29 (58%) 21 (42%)
3 27 13 (48.1%) 14 (51.9%)
Lymph nodes
ve 25 12 (38%) 13 (52%) 0.455
+ve 58 33 (56.9%) 25 (43.1%)
Depth of invasion
T1 7 0 7 (100%) 0.008
T2 13 5 (38.5%) 8 (61.5%)
T3 23 14 (60.9%) 9 (39.1%)
T4 40 26 (65%) 14 (35%)
H. pylori infection
+ve 69 41 (59.4%) 28 (40.6%) 0.035
ve 14 4 (28.6%) 10 (71.4%)
* NA, not applicable.
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Previous studies have concluded that COX-2 and VEGF
expressions played important roles in the growth and metasta-
sis of many human tumors including gastrointestinal cancers.
Because of their high expression in tumors, they constitute
potential targets in cancer prevention and treatment. Their
expressions were also associated with a variety of clinicopatho-
logical parameters [3,6,12,13]. However, these associations
remained controversial as some studies showed no such associ-
ation [14,15]. These studies prompted us to evaluate COX-2
and VEGF expression at protein levels in tissues with GC
and assess the relationship with clinicopathological data.
Several studies have reported that COX-2 expression is ele-
vated in GC when compared with control normal mucosae
[3,6,8,13,16,17]. Our results were concordant with this previous
observation, conﬁrming that COX-2 protein plays an impor-
tant role in gastric carcinogenesis.In the present study, COX-2 protein expression was
detected in 54.2% of the studied GC cases. This ﬁnding was
comparable to previous studies [3,8]. Higher and lower expres-
sion ﬁgures were reported by others [13,15,6]. These discrepan-
cies may be related to the use of different scoring systems,
change in speciﬁcity and sensitivity of antibodies employed
in IHC or patient heterogeneity. Another possibility was sug-
gested by Wang et al., 2014 [18] and Sierra et al., 2013 [19]
who reported that H. pylori infection causes up-regulation of
COX-2 mRNA expression in GC cases. Since it is proven that
H. pylori infection varies from area to area in the world, the
expression of COX-2 protein also varies. In an agreement with
these conclusions, 59.4% of our H. pylori infected cases were
positive to COX-2 protein. Hussein, 2010 [20] observed reduc-
tion, but not elimination, in COX-2 expression after treatment
of H. pylori infection.
Among the 34 cases of intestinal metaplasia and the 10
cases with dysplasia in neighboring mucosae, 16 cases
Table 4 Relationship between VEGF expression and the clinicopathological factors of the 38 studied GC cases.
Clinicopathological factors Total VEGF expression P value
+ve (n= 57) ve (n= 26)
Age
<60 years 44 28 (63.6%) 16 (36.4%) 0.293
P60 years 39 29 (74.4%) 10 (25.6%)
Sex
Male 60 42 (70%) 18 (30%) 0.674
Female 23 15 (65.2%) 8 (34.8%)
Location
Antrum 41 30 (73.2%) 11 (26.8%) 0.847
Body 20 13 (65%) 7 (35%)
Fundus 17 11 (64.7%) 6 (35.3%)
Cardia 5 3 (60%) 2 (40%)
Lauren classiﬁcation
Intestinal type 45 30 (66.7%) 15 (33.3%) 0.668
Diﬀuse type 38 27 (71.1%) 11 (28.9%)
Histologic subtypes
Tubular adenocarcinoma 33 22 (66.7%) 11 (33.3%) NA*
Papillary adenocarcinoma 6 4 (66.7%) 2 (33.3%)
Mucinous adenocarcinoma 7 5 (71.4%) 2 (28.6%)
Signet ring adenocarcinoma 31 22 (71%) 9 (29%)
Undiﬀerentiated carcinoma 6 4 (66.7%) 2 (33.3%)
Grade
1 6 4 (66.7%) 2 (33.3%) 1.000
2 50 34 (68%) 16 (32%)
3 27 19 (70.4%) 8 (29.6%)
Lymph nodes
ve 25 10 (40%) 15 (60%) <0.001
+ve 58 47 (81%) 11 (19%)
Depth of invasion
T1 7 2 (28.6%) 5 (71.4%) <0.001
T2 13 3 (23.1%) 10 (78.9%)
T3 23 17(73.9%) 6 (26.1%)
T4 40 35 (87.5%) 5 (12.5%)
H. pylori infection
+ve 69 48 (69.6%) 21 (30.4%) 0.698
ve 14 9 (64.3%) 5 (35.7%)
* NA, not applicable.
Table 5 Relationship between COX-2 and VEGF immunos-
taining in the studied cases of GC.
VEGF expression COX-2 expression Kappa value
+ve ve
+ve 42 (50.6%) 15 (18.1%) 0.55
ve 3 (3.6%) 23 (27.7%)
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2 (scores+), respectively. These ﬁndings conﬁrmed previous
observations that COX-2 might be involved in the early stages
of gastric cancer development [21]. Our result was almost con-
cordant with others who reported immunoreactivity for COX-
2 protein in 37.8% of cases with intestinal metaplasia and
41.7%, of intestinal dysplasia cases. They found that COX-2
expression in the metaplasia or dysplasia tissues was relatedto H. pylori infection [18]. In our series, 12 out of 16 (75%)
COX-2 positive intestinal metaplasia cases and 100% of dys-
plasia positive cases were infected with H. pylori.
Our data revealed that COX-2 was expressed predomi-
nantly by the intestinal type GC in contrast to carcinoma of
diffuse type (p< 0.001). Similarly, this ﬁnding was concordant
with most of the previous studies [8,13,17,22]. The explanation
of these results was related to the fact that H. pylori infection
has been identiﬁed in almost 90% of intestinal type carcinoma
which induced COX-2 expression in GC cells [18,22]. In the
present study, H. pylori infection was identiﬁed in 100% of
COX-2 positive intestinal type GC. However, this outcome
was inconcordant with the results reported in a previous study
[3].
This study indicated that the expression of COX-2 was sig-
niﬁcantly associated with deeper depth of invasion (p= 0.008)
suggesting that this protein might be involved in the local pro-
gression of GC. This result was consistent with other reports
[7,8,13,16] yet contradicted with others’ [3,15].
Figure 1 Immunohistochemical staining of COX-2 in tubular adenocarcinoma showing score++ positivity (200).
Figure 2 Immunohistochemical staining of COX-2 in undiffer-
entiated carcinoma revealed score+ positivity (400).
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signiﬁcantly low in the signet-ring adenocarcinoma (32.3%)
and in undifferentiated carcinoma (16.7%).Figure 3 Strong cytoplasmic expression of COX-2In agreement with others [14,15,17], no signiﬁcant associa-
tion was found between COX-2 expression and age, sex, tumor
location, grade and lymph node status. These results were not
in concert with the results of Lazar et al. (2008) [8] who
revealed that COX-2 expression was signiﬁcantly associated
with tumor differentiation and lymph node status. Others
reported an association between COX-2 expression and tumor
grade [13]. Mao et al. (2007) [16] demonstrated that the expres-
sion was related to lymph nodes metastasis. Thiel et al. (2011)
[23] concluded that the COX-2 expression is more frequent in
proximal than in distal gastric location.
Tumor angiogenesis and its clinical signiﬁcance have been
evaluated in many human cancers. VEGF was conﬁrmed to
be a useful marker for the assessment of angiogenesis [12,13].
Based on our IHC evaluation, VEGF were highly expressed
in GC tissues, but not in control normal mucosae. The differ-
ence in the expression was extremely signiﬁcant (p< 0.001).
Our result was in line with previous publications
[12,13,17,24,25].
Cytoplasmic staining for VEGF was observed in 68.7% of
the studied GC cases. Our ﬁndings were similar to other stud-
ies [9,12,26] but higher than results of others [10,27,28]. Zhao
et al. (2006) [13] reported a higher positivity rate of 76.1%.in signet ring adenocarcinoma, score++ (200).
Figure 5 Immunohistochemical staining of VEGF in signet ring
adenocarcinoma showing score+ positivity (400).
Figure 4 Immunohistochemical staining of VEGF in tubular adenocarcinoma showing score++ positivity (200).
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ple size, different scoring system, different antibodies used or
patient heterogeneity.
In the current study, 10 out of 34 cases with intestinal meta-
plasia in the adjacent mucosa (29.4%) were weakly positive for
VEGF (score+). Positive reaction was also found in 6 out of
10 (60%) cases with gastric dysplasia. In the same context,
others found positivity in 28.6% and 66.7% of their studied
intestinal metaplastic and dysplasia cases and they reported
that it is the expression of an early tumor angiogenesis during
the natural evolution from the normal mucosa to carcinoma
[29].
We related VEGF expression to clinicopathological data of
the studied GC cases. Expression of VEGF was found to be
signiﬁcantly linked to the depth of invasion (p< 0.001) and
lymph node metastasis (p< 0.001). These results indicated
that VEGF promoted GC local invasion and metastasis. Our
results were in agreement with the results obtained by others
[12,17,26]. However, other researchers failed to prove these sig-
niﬁcant relations [9,24]. In the current study, we did notobserve a statistically signiﬁcant relation between VEGF over-
expression and some clinicopathological features, such as age,
sex, location, grade, Lauren classiﬁcation, histological sub-
types and H. pylori infection (p> 0.05). Our results were con-
ﬁrmed by others [15,17]. Previous studies have demonstrated a
positive association with tumor location [28] as well as histo-
logical type and grade [13,25]. Others reported a positive rela-
tion between VEGF expression in and H. pylori gastric cancer
cells [29].
In order to evaluate the contribution of COX-2 expression
to tumor angiogenesis, we have evaluated the association
between the VEGF and COX-2 expression. Our result revealed
a positive association (Kappa value = 0.55). These data sug-
gest that COX-2 is involved in the development of angiogene-
sis in GC cases through VEGF upregulation. Our results were
in agreement with previous studies where COX-2 expression
was signiﬁcantly associated with VEGF [13,30]. In contrary
to the above results, a study has shown no relationship [15].
Similar association was reported in lung adenocarcinoma cases
and in breast carcinoma [31].
In conclusion, our study demonstrates that expression of
COX-2 and VEGF is signiﬁcantly higher in GC compared to
control samples. They might be used as biomarkers predicting
tumor behavior and prognosis in GC. COX-2 expression is sig-
niﬁcantly related to intestinal type carcinoma, locally
advanced disease and H. pylori infected patients. VEGF
expression is signiﬁcantly associated with loco-regional pro-
gression. VEGF showed signiﬁcant association with the
expression of COX-2 suggesting the involvement of COX-2
in tumor angiogenesis.
In the current study, there was an important limitation that
needs to be addressed. The sample size was relatively small;
therefore, it is not possible to reliably conclude that there were
no associations between biomarkers and different clinico-
pathological parameters. Further works with larger sample
size are required to evaluate the negative relationships.Conflict of interest
None declared.
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